Search

Your search keyword '"Eulàlia Genescà"' showing total 4 results
Start Over Author "Eulàlia Genescà" Publisher ferrata storti foundation
4 results on '"Eulàlia Genescà"'

1. Unique clinico-biological, genetic and prognostic features of adult early T-cell precursor acute lymphoblastic leukemia

Author

Eulàlia Genescà, Mireia Morgades, Pau Montesinos, Pere Barba, Cristina Gil, Ramon Guàrdia, María-José Moreno, Daniel Martínez-Carballeira, Irene García-Cadenas, Susana Vives, Jordi Ribera, José González-Campos, Celia González-Gil, Lurdes Zamora, José-Luís Ramírez, Marina Díaz-Beya, Santiago Mercadal, María-Teresa Artola, Antònia Cladera, Mar Tormo, Arancha Bermúdez, Ferran Vall-Llovera, Pilar Martínez, María-Luz Amigo, Silvia Monsalvo, Andrés Novo, Marta Cervera, Antoni García-Guiñon, Jordi Juncà, Juana Ciudad, Alberto Orfao, and Josep-Maria Ribera

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2020
Full Text
View/download PDF

2. Contribution of copy number to improve risk stratification of adult T-cell acute lymphoblastic leukemia patients enrolled in measurable residual disease-oriented trials

Author

Celia Gonzalez-Gil, Mireia Morgades, Thaysa Lopes, Francisco Fuster-Tormo, Pau Montesinos, Pere Barba, Marina Diaz-Beya, Lourdes Hermosin, Clara Maluquer, Jose Gonzalez-Campos, Teresa Bernal, Marta Sitges Arriaga, Lurdes Zamora, Marta Pratcorona, Rodrigo Martino, Maria Jose Larrayoz, Teresa Artola, Anna Torrent, Ferran Vall-llovera, Mar Tormo, Cristina Gil, Andres Novo, Pilar Martinez-Sanchez, Jordi Ribera, Maria-Paz Queipo, Teresa Gonzalez-Martinez, Monica Cabrero, Antonia Cladera, Jose Cervera, Alberto Orfao, Josep Maria Ribera, and Eulalia Genesca

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Abstract

Not available.

Published
2024
Full Text
View/download PDF

3. TIM3, a human acute myeloid leukemia stem cell marker, does not enrich for leukemia-initiating stem cells in B-cell acute lymphoblastic leukemia

Author

Clara Bueno, Alba Martínez, Paola Alejandra Romecin, Samanta Romina Zanetti, Ricky Tirtakusuma, Eulalia Genesca, Mireia Camós, Manuel Ramírez-Orellana, Eduardo Anguita, Paola Ballerini, Franco Locatelli, José Luis Fuster, and Pablo Menéndez

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2023
Full Text
View/download PDF

4. Genomics improves risk stratification of adults with T-cell acute lymphoblastic leukemia enrolled in measurable residual disease-oriented trials

Author

Celia González-Gil, Mireia Morgades, Thaysa Lopes, Francisco Fuster-Tormo, Jesús García-Chica, Ran Zhao, Pau Montesinos, Anna Torrent, Marina Diaz-Beya, Rosa Coll, Lourdes Hermosín, Santiago Mercadal, José González-Campos, Lurdes Zamora, Teresa Artola, Ferran Vall-Llovera, Mar Tormo, Cristina Gil-Cortés, Pere Barba, Andrés Novo, Jordi Ribera, Teresa Bernal, Paula López de Ugarriza, María-Paz Queipo, Pilar Martínez-Sánchez, Alicia Giménez, Teresa González-Martínez, Antonia Cladera, José Cervera, Rosa Fernández-Martín, María Ángeles Ardaiz, María Jesús Vidal, Ángela Baena, Nuria López-Bigas, Anna Bigas, Jaroslaw Maciejewski, Alberto Orfao, Josep Maria Ribera, and Eulalia Genescà

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Abstract

Genetic information has been crucial to understand the pathogenesis of T-cell acute lymphoblastic leukemia (T-ALL) at diagnosis and at relapse, but still nowadays has a limited value in a clinical context. Few genetic markers are associated with the outcome of T-ALL patients, independently of measurable residual disease (MRD) status after therapy. In addition, the prognostic relevance of genetic features may be modulated by the specific treatment used. We analyzed the genetic profile of 145 T-ALL patients by targeted deep sequencing. Genomic information was integrated with the clinicalbiological and survival data of a subset of 116 adult patients enrolled in two consecutive MRD-oriented trials of the Spanish PETHEMA (Programa Español de Tratamientos en Hematología) group. Genetic analysis revealed a mutational profile defined by DNMT3A/ N/KRAS/ MSH2/ U2AF1 gene mutations that identified refractory/resistant patients. Mutations in the DMNT3A gene were also found in the non-leukemic cell fraction of patients with T-ALL, revealing a possible mutational-driven clonal hematopoiesis event to prime T-ALL in elderly. The prognostic impact of this adverse genetic profile was independent of MRD status on day +35 of induction therapy. The combined worse-outcome genetic signature and MRD on day +35 allowed risk stratification of T-ALL into standard or high-risk groups with significantly different 5- year overall survival (OS) of 52% (95% confidence interval: 37-67) and 17% (95% confidence interval: 1-33), respectively. These results confirm the relevance of the tumor genetic profile in predicting patient outcome in adult T-ALL and highlight the need for novel gene-targeted chemotherapeutic schedules to improve the OS of poor-prognosis T-ALL patients.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results